Advice
Following an abbreviated submission
Clarithromycin as Clarosip granules for oral suspension is not recommended for use within NHS Scotland for the treatment of acute and chronic infections caused by clarithromycin susceptible organisms.
It uses sip technology, where the granules are contained within a drinking straw. Clarosip incurs a cost premium of up to 20% compared to alternative oral liquid clarithromycin, with no proven advantage in terms of compliance
Download detailed advice29KB (PDF)
Medicine details
- Medicine name:
- Clarithromycin 125 mg, 187.5 mg, 250 mg granules for oral suspension (ClaroSip®)
- SMC ID:
- 217/05
- Indication:
- Acute and chronic infections caused by clarithromycin susceptible organisms
- Pharmaceutical company
- Grünenthal Ltd
- BNF chapter
- Infections
- Submission type
- Abbreviated
- Status
- Not recommended
- Date advice published
- 13 February 2006